The vesicular monoamine transporter type 2 gene (VMAT2) has a crucial role in the storage and synaptic release of all monoamines, including serotonin (5-HT). To evaluate the specific role of VMAT2 in 5-HT neurons, we produced a conditional ablation of VMAT2 under control of the serotonin transporter (slc6a4) promoter. VMAT2 sertÀcre mice showed a major (À95%) depletion of 5-HT levels in the brain with no major alterations in other monoamines. Raphe neurons contained no 5-HT immunoreactivity in VMAT2 sertÀcre mice but developed normal innervations, as assessed by both tryptophan hydroxylase 2 and 5-HT transporter labeling. Increased 5-HT 1A autoreceptor coupling to G protein, as assessed with agonist-stimulated [ 35 S]GTP-g-S binding, was observed in the raphe area, indicating an adaptive change to reduced 5-HT transmission. Behavioral evaluation in adult VMAT2 sertÀcre mice showed an increase in escape-like reactions in response to tail suspension and anxiolytic-like response in the novelty-suppressed feeding test. In an aversive ultrasoundinduced defense paradigm, VMAT2 sertÀcre mice displayed a major increase in escape-like behaviors. Wild-type-like defense phenotype could be rescued by replenishing intracellular 5-HT stores with chronic pargyline (a monoamine oxidase inhibitor) treatment. Pargyline also allowed some form of 5-HT release, although in reduced amounts, in synaptosomes from VMAT2 sertÀcre mouse brain. These findings are coherent with the notion that 5-HT has an important role in anxiety, and provide new insights into the role of endogenous 5-HT in defense behaviors.
INTRODUCTION
Serotonin (5-HT) has a central importance in the control of mood and anxiety states (Lucki, 1998) . Dysfunctions of 5-HT neurotransmission can result from alterations at several critical points of monoamine metabolism such as synthesis, release, reuptake, catabolism, or serotonin receptors (Morilak and Frazer, 2004) . All these constitute entry points to pharmacological therapeutic approaches (Berton and Nestler, 2006) and to genetic variations that impact disease predisposition. Vesicular monoamine transporters (VMATs) seem important targets with regard to the neurobiology of mood. Indeed, the initial formulation of the monoamine theory of depression was derived from studies with reserpine, an irreversible VMAT blocker, prescribed as an antihypertensive agent, subsequently found to cause depression in humans (Freis, 1954) . Moreover, there is evidence for a link of depression to genetic polymorphism of the VMAT2 gene (Christiansen et al, 2007; Gutierrez et al, 2007) . The main function of VMAT is to concentrate biogenic amines into intracellular storage organelles such as synaptic vesicles, shielding them from degradation, and concentrating them for release into the synaptic cleft (Henry et al, 1998) . Nevertheless, 5-HT can also function as a paracrine transmitter by acting on receptors distant from synaptic release sites (Bunin and Wightman, 1999) , and non-vesicular release of neurotransmitters is known to occur under some physiological conditions (Attwell et al, 1993; Wu et al, 2007) .
VMATs exist as two different isoforms: VMAT1 mainly expressed in chromaffin and enterochromaffin cells and VMAT2 essentially expressed in monoaminergic neurons (Erickson et al, 1996; Erickson and Eiden, 1993) . Microdialysis (Adell and Artigas, 1998) and voltametry (Bunin et al, 1998 ; O'Connor and Kruk, 1991) experiments showed that tetrabenazine, a selective VMAT2 blocker, prevents the release of 5-HT in the raphe and in axon terminal fields, whereas VMAT2-KO mice showed no release of amines (Fon et al, 1997; Wang et al, 1997) . VMAT2-KO mice do not survive beyond the first postnatal days Fon et al, 1997; Wang et al, 1997) preventing the long-term evaluation of the consequences of a lack of monoamine/5-HT release. VMAT2 heterozygous mice with rather small (20-30%) reductions in brain amines showed no change in anxiety-like behaviors, but indications of a 'depression-like' phenotype (Fukui et al, 2007) . However, it was unclear whether this phenotype was linked to a reduced release of 5-HT or of other amines (dopamine (DA), noradrenaline (NA), histamine) that also depend on VMAT2 for vesicular storage.
To overcome this limitation, we generated a conditional deletion of VMAT2 that allowed investigating the role of this transporter specifically in 5-HT neurons. Specific ablation of VMAT2 in raphe 5-HT neurons was obtained by Cre recombinase expressed under the control of the 5-HT transporter gene (SERT, slc6a4) promoter. We report that VMAT2 sertÀcre mice have a near complete depletion of 5-HT in the brain, consequent to abolished vesicular 5-HT uptake. Raphe neurons develop normally and show a normal innervation of target areas. A consequence of sustained 5-HT depletion was to increase the coupling of 5-HT 1A autoreceptors with its G protein, a known sensitive index of chronic changes in 5-HT levels. Behavioral observations in adults indicated that abolished synaptic 5-HT release caused anxiolytic-like phenotype, while increasing reactivity to innately aversive stimuli. The latter alteration was reversed by a 3-week treatment with pargyline, a monoamine oxidase inhibitor (MAOI), which markedly increased brain 5-HT levels. These observations are coherent with the notion that elevated levels of endogenous 5-HT in stressful situations can inhibit prepotent behaviors and is linked to anxiety (Gray and McNaughton, 2000) . This study established VMAT2 
MATERIALS AND METHODS

Animals
Procedures involving animals and their care were conducted in accordance with the directives of the European Community (council directive 86/609) and the French Agriculture and Forestry Ministry (council directive 87-848, 19 October 1987, permissions 75-977 to LL and 00782 to PG) .
The floxed VMAT2 mouse line was produced at the Mouse Clinical Institute (Institut Clinique de la Souris, MCI/ICS, Illkirch, France) in coordination with unit Inserm U952 (Bruno Giros, to whom correspondence regarding the mouse line should be addressed: bruno.giros@inserm.fr). A 9-kb fragment of the VMAT2 gene encompassing exons 1-3 was subcloned into the targeting vector and the two loxP sites and the neomycin-selectable cassette flanked by two FRT sites were introduced in introns flanking the first coding exon. Embryonic stem cells were electroporated with the targeting vector and cell clones resistant to selection were screened by PCR and Southern analysis to identify clones that resulted from a correct targeting event (2/744 clones analyzed). Excision of the neomycin cassette was performed in vivo by crossing chimeric mice with transgenic mice expressing the Flp recombinase under control of the early b-actin promoter. The presence of the floxed allele in the progeny was screened by PCR. VMAT2 lox/lox mice were maintained on a C57BL/6J background.
The SERT cre mouse line has been described previously (Zhuang et al, 2005) . This is a gene trap construction, which replaces exon 14 of the serotonin transporter gene (SERT) with a gene sequence encoding cre-recombinase. Previous studies have shown that recombination occurs by E12 in the raphe neurons (Narboux-Neme et al, 2008) and that virtually all tryptophan hydroxylase 2 (TPH2) neurons in the raphe have recombined in postnatal life (Zhuang et al, 2005 :: SERT cre/ + (control 2). After weaning and sexing, males and females were housed separately in groups of 6-8 animals per cage and maintained under standard laboratory conditions (22 ± 1 1C, 60% relative humidity, 12-12 h lightdark cycle, food and water ad libitum). Male mice were used at 2-3 months of age when their body weight in each genotype equally ranged between 20 and 25 g (NarbouxNême et al, 2009). Some histological assays (VMAT and 5-HT immunohistochemistry) were performed on P7 mice for early detection of the phenotype, which was found the same at adult ages. In addition, some C57BL/6J mice (purchased from Janvier, France) were used for pharmacological studies.
Neurotransmission Studies
Tissue levels of 5-HT, 5-hydroxyindolacetic acid (5-HIAA), NA, and DA were determined using high-pressure liquid chromatography with electrochemical detection (HPLC-ED) as described previously (Mongeau et al, 2010) . Crude synaptosomes from VMAT2 sertÀcre and control mice, prepared as described previously (Gray and Whittaker, 1962) , were used in experiments for measurements of [ 3 H]5-HT uptake and release induced with the releasing agent 3,4-methylenedioxymethamphetamine (MDMA: 0.1 nM-10 mM) or potassium (3-100 mM). Quantitative autoradiography of 5-HT 1A receptor-mediated [ 35 S]GTP-g-S binding using the non-selective agonist 5-carboxamidotryptamine (5-CT; 10-1000 nM; non-specific binding defined by WAY 100635) was performed as described previously (Fabre et al, 2000) . See Supplementary online information for further details.
Histological Analyses
Mice were perfused transcardiacally with 4% paraformaldehyde, and their brains were postfixed overnight in 4% paraformaldehyde, cryoprotected in 30% sucrose, and serially sectioned (60-mm thick sections) on a freezing microtome. Alternate series for immunohistochemistry, in situ hybridization, and counterstaining were used.
VMAT2 conditional deletion N Narboux-Nême et al Immunohistochemistry was performed using specific antibodies against VMAT2 (1 : 10 000, Phoenix), 5-HT (1 : 50 000, Sigma), and SERT (1 : 1000, Calbiochem) as described previously . Secondary antibodies used were biotinylated anti-rabbit IgG (1 : 300, Jackson Laboratories) followed by avidin-biotin-peroxidase complex (1 : 400, Amersham). Peroxidase activity was detected with 3,3 0 -diaminobenzidine peroxide. In situ hybridization experiments were performed as described previously (Bally-Cuif and Wassef, 1994) . The TPH2 c-DNA plasmid described previously (Cote et al, 2003) was donated by P Ravassard (CRICM, UPMC, Paris).
Images were captured using a Cool Snap FX camera fitted to a Leica DM RD microscope under consistent light conditions using 20 Â /0.70 objectives. Images were copied to 8-bit RGB digital format and analyzed using ImageJ software. The density of SERT-immunoreactive fibers was estimated by counting the number of intersecting fibers with a grid composed of hemicycloids, as described previously (Gaspar et al, 1991) . The density of TPH2-labeled neurons was estimated in two sections through the rostral portion of the dorsal raphe nucleus. All neurons contained in a grid of 250 Â 250 mm 2 were counted. The grid was placed over three different areas of the dorsal raphe, for each case.
Behavioral Testing
Experiments were carried out in adult (2-4 months) VMAT2 sertÀcre mice and controls from the same litters that included both VMAT2 ) and the apparatus was 38.5 cm above the floor. To initiate the 5-min test session, the mouse was placed on the central platform, facing an open arm. The mouse was considered to be on the central platform whenever two paws were on it, and in one of the arms when all four paws were inside. Behavioral analysis was performed using a video recording using ODlog (Macropod Software) by an observer unaware of the genotype. Results are reported as the time spent and the number of entries in the open arms to assess anxiety-like behavior, and total number of entries into both open and closed arms to assess locomotor activity.
Spontaneous locomotor activity. Locomotor activity was measured using a computer-based photobeam apparatus (Actisystem II, Panlab, Barcelona, Spain). Actimeter box (area: 300 Â 150 mm 2 ; height 180 mm; with plexiglass wall and grid floor) detected mouse movements by means of two infrared light beams. Mice were placed in the testing room at least 2 h before the experiment.
Novelty-suppressed feeding. Animals were placed one per cage for at least 1 week, and their bedding was changed just before food deprivation. All mice were deprived of their regular food for 48 h and placed in the testing room for at least 1 h before the test. They were then placed into an unfamiliar arena (area: 400 Â 400 mm 2 ; height 180 mm; containing bedding) with a small plate containing food at the center of the field. Latency to feed was measured using a video recording, from the time the mouse is placed in the periphery of the arena until the animal began feeding. Latency to feed was also measured in the home cage, to assess whether changes in latency might be accounted for by alteration in the feeding drive rather than reaction to the anxiogenic environment. The delay was measured from the time the mouse was placed at the periphery of the cage containing the food in the center.
Food consumption. Animals were placed one per cage for 1 week before measuring daily food intake over 1 week. The pellets consumed were measured by weighing the amount of remaining food each day.
Tail suspension test. The apparatus consists of three suspension units divided by walls (ID-Tech-Bioseb, Chaville, France). Mice were suspended by the tail, using an adhesive tape attached to a strain gauge transducing movements into a signal transmitted to a central unit for signal digitalization. Although VMAT2 sertÀcre mouse weights differ from controls during postnatal life (NarbouxNême et al, 2009), weight differences were no longer observed at adult age which eliminates any bias in measurements with this test. The duration of immobility was measured automatically by the software over a 6-min period. Struggling duration was analyzed from the traces generated by the software, and was defined as the total time the mouse spent in activity burst (ie, excluding all the small movements), during the 6-min test period. Activity burst was defined as a force exerted on the transducer X3 g above the baseline value for 42 s.
Ultrasound-induced defense reactions. Mice were tested for their innate fear reactions to a train of ultrasonic stimuli (US), as described previously (Mongeau et al, 2003) . Animals were placed one per cage for at least 1 week before testing. In brief, 100 ms frequency sweeps between 17 and 20 kHz, 85 dB, alternately ON 2 s and then OFF 2 s for 1 min were delivered into the home cage (18 Â 29 cm 2 ) after a 3-min baseline period. Flight reactions triggered during ON periods were measured as the number of running events from one side of the cage to the other followed by behavioral arrest, whereas the percentage time freezing to the US was quantified by sampling events of complete immobility (except respiration) every 4 s during the OFF period. These defense behaviors were measured from a video file by an observer unaware of mouse genotype.
Pargyline Treatment
Mice were treated using subcutaneous osmotic minipumps (Alzet model 2004) to avoid injection handling which alters mice spontaneous defense behaviors to the US. Chronic pargyline treatment was carried out to achieve sustained MAOA and MAOB inhibition and optimally enhanced 5-HT neurotransmission in both control and VMAT2 sertÀcre mice. Pargyline (70 mg/kg Â day; Fluka, Buchs, Switzerland) or vehicle (water) was administered for 3 weeks using 
Statistics
Data were analyzed using Student's t-test when comparing two groups. The [ 35 S]GTP-g-S binding data and the effects of pargyline treatment on 5-HT levels and flight behaviors in relation to the genotype were analyzed using two-way ANOVA, followed by Bonferonni's post hoc test. EC 50 values were compared by one-way ANOVA, followed by Bonferonni's test. Statistical significance was set at po0.05.
RESULTS
Specific Invalidation of the VMAT2 Gene in 5-HT Neurons
Conditional ablation of VMAT2 was obtained by inserting loxP sequences into the genomic sequence of the VMAT2 gene by homologous recombination, which produced the new mouse line VMAT2 lox/lox ( Figure 1 ). These mice were crossed to a previously described mouse line in which the 5-HT transporter (SERT, Slc6a4) promoter drives the expression of bacterial Cre recombinase (Narboux-Neme sertÀcre ') was amplified for analysis. As with other 5-HT-depleted transgenic mice (Alenina et al, 2009; Trowbridge et al, 2010) , there was an increased mortality of VMAT2 sertÀcre mice between P1 and P30 compared with control mice.
We first checked the effectiveness and selectivity of Cremediated excision using an antiserum that specifically stains the VMAT2 isoform. In wild-type (C57BL/6J) and VMAT2 lox/lox mice, immunolabeling was observed in neurons of the raphe, the locus coeruleus, the substantia nigra, and the hypothalamus (Figure 2a) . In VMAT2 sertÀcre mice (Figure 2a ), VMAT2 immunostaining was abolished in raphe neurons but was still present in noradrenergic neurons of the locus coeruleus, in dopaminergic neurons of the substantia nigra. Similarly, VMAT2 immunostaining was unchanged in the hypothalamus and histamine neurons (Figure 2a) . No visible reduction in VMAT2 immunostaining was detected in heterozygote mice lacking only one allele of the VMAT2 gene (VMAT2 lox/ + :: SERT cre/ + ; data not shown).
5-HT immunocytochemistry showed a major and uniform depletion of 5-HT immunostaining in all axon terminal fields ( Figure 2b ) with very faint residual staining in raphe neurons in the brainstem in P7 mice ( Figure 2b ) and a complete lack of labeling in the adult raphe. However, the density of TPH2-positive neurons, in the rostral part of the dorsal raphe nucleus, was unchanged (Figure 2c ). To assess raphe projections, immunolabeling was performed with anti-SERT antibodies. Examination of serial coronal sections through the brain showed a comparable distribution and morphology of SERT-labeled axons in VMAT2 sertÀcre and control brains. The density of SERT-labeled axons was estimated in the cerebral cortex and hippocampus. This showed no difference in fiber density between control and mutants ( Figure 2c) . Overall, these results indicated that 5-HT raphe neurons developed normally in VMAT2 sertÀcre mutants compared with WT mice.
Consequences on Monoamines Metabolism, Uptake, and Signal Transduction
Tissue monoamine levels were measured by HPLC in various brain areas (such as the cortex, striatum, hippocampus, brainstem), gut, and blood, as these tissues are known to produce or contain large amounts of 5-HT. Monoamines levels were not significantly different in wildtype (C57BL/6J), VMAT2 lox/lox , and VMAT2 lox/ + /SERT cre/ + mice, which lack one allele of VMAT2 (results not shown); hence, in subsequent studies, VMAT2 lox/lox and the VMAT2 lox/ + /SERT cre/ + mice were pooled as controls. Dramatic decreases in 5-HT levels were observed throughout the brains of VMAT2 sertÀcre mice (from À92 to À96%), with no significant differences between brain structures (Figure 3a, left) . Remarkably, no changes in 5-HIAA levels were observed (Figure 3a, right) . This suggests (with data of Figure 2c ) that 5-HT was produced in normal amounts. DA levels in the striatum and NA levels in the hippocampus and the cortex ( Figure 3) were not or only marginally altered, although there was a 17±3% (po0.01) decrease of hippocampal NA in VMAT2 sertÀcre mice (that could be explained by a lack of stimulatory action of 5-HT on NA terminals in that area (Mongeau et al, 1994) ) as compared with controls ( Figure 3b ). By contrast, 5-HT levels were normal in the gut (Figure 3c) , consistent with the fact that enterochromaffin cells express VMAT1 rather than VMAT2 (Erickson et al, 1996) . A different situation occurred in the blood in which a 80 ± 3% (po0.001) decrease in 5-HT levels was noted (Figure 3c) , consistent with the notion that platelets use VMAT2 rather than VMAT1 to store 5-HT (Holtje et al, 2003) .
The release of endogenous 5-HT was examined in synaptosome preparations obtained from the whole brain. VMAT2 conditional deletion N Narboux-Nême et al potassium-induced release were also analyzed on synaptosomes from control, SERT cre/ + , and VMAT2 sertÀcre mice (Figure 4b-d) . After loading, [
3 H]5-HT is normally distributed between two compartments, a fraction in the storage vesicles and another fraction in the axoplasm. The MAOI pargyline (0.1 mM) was added to the medium to prevent degradation of [ In VMAT2 sertÀcre synaptosomes, uptake of [ 3 H]5-HT was reduced to a similar level as that observed in reserpine (0.1 mM)-treated synaptosomes from WT mice (Figure 4b ). In contrast, no significant alterations were noted in SERT cre/ + synaptosomes. MDMA-induced release, occurring through the reversal of the reuptake carrier (Hekmatpanah and Peroutka, 1990; McKenna et al, 1991; Renoir et al, 2008) , was analyzed in synaptosomes from WT and VMAT2 sertÀcre mice compared with WT mice (Figure 4b ). There was a small but sertÀcre mice. Coronal sections at comparable levels in the raphe, the locus coeruleus, the substantia nigra, and the hypothalamus from P7 mice. VMAT2 immunostaining is abolished in the raphe neurons of VMAT2 sertÀcre mice compared with control mice, whereas immunostaining is unchanged in the noradrenergic, the dopaminergic, or the histaminergic neurons in the other brain areas. VMAT2 conditional deletion N Narboux-Nême et al significant change in the concentration of MDMA that triggers 50% release in VMAT2 sertÀcre mice compared with control mice (Figure 4c ): the dose-response curve was slightly shifted to the left when using VMAT2 sertÀcre synaptosomes (Àlog EC 50 : VMAT2 sertÀcre ¼ 7.35 ± 0.11; WT ¼ 6.86 ± 0.09, n ¼ 3, po0.01). A similar change compared with WT synaptosomes was found in WT synaptosomes treated with reserpine (Àlog EC 50 : WT+ reserpine ¼ 7.26 ± 0.11, po0.05), but not in synaptosomes from SERT + /cre mice (Àlog EC 50 : 6.69 ± 0.14; Figure 4c ). However, the concentration of KCl necessary to trigger 50% of maximal release of [ Potassium-induced release is only weakly dependent on the presence of calcium in the media under the abovedescribed conditions (varying from 0 to 30% at 3-100 mM of KCl; not shown), suggestive of non-vesicular release. Other experimental conditions were used to test calciumdependent release. This involved the retrieval of pargyline from the media and shorter potassium pulses (30 s). Under these conditions, we observed a calcium-dependent release of [ Figure 4e as a decrease in the amount of radioactivity in synaptosomes after KCl stimulation) in WT mice, whereas no significant calciumdependent vesicular release was found in synaptosomes from VMAT2 sertÀcre mice. To assess whether adaptive changes occur at 5-HT receptors as a consequence of VMAT2 sertÀcre 5-HT depletion, we measured 5-HT 1A receptor-stimulated [
H]5-HT (indicated in
35 S]GTP-g-S binding using 5-CT as the agonist (Fabre et al, 2000) . [
35 S]GTP-g-S binding was significantly increased in the dorsal raphe nucleus in response to 5-HT 1A receptor activation by 5-CT in VMAT2 sertÀcre compared with control mice (po0.0001, two-way ANOVA, Figure 5a ), suggesting an upregulation of 5-HT 1A autoreceptors and/or enhanced coupling efficacy of these autoreceptors to G proteins. In contrast, no change in 5-CT-induced [
35 S]GTP-g-S binding was found in post-synaptic sites, such as the dorsal hippocampus (Figure 5b) , the ventral hippocampus, and the septum (not shown).
Behavioral Consequences
We measured the consequences of VMAT2 sertÀcre -induced 5-HT depletion in standard models of anxiety and depression. In the elevated plus maze (EPM), VMAT2 sertÀcre mice spent the same amount of time exploring the open arms as did control mice (Figure 6a ). However, there was a significant decrease (À37±7%; po0.05) in the overall entries into both the closed and the open arms (Figure 6a ) suggesting a change in locomotor activity that could confound the interpretation of the EPM data. Indeed, specific assessment of locomotion with an actimeter also showed a 40% reduction in spontaneous locomotor activity of VMAT2 sertÀcre mice (Figure 6b ). To further explore the anxiety-related phenotype in a model less dependent on locomotion, we applied the novelty-suppressed feeding (NSF) test, in which there is a conflict between the feeding drive and risk assessment behaviors. VMAT2 sertÀcre mice initiated to feed much sooner (about three times faster; Figure 6c ) than did control mice in the unfamiliar cage but not in the home cage, indicating an anxiolytic-like phenotype, rather than a change in appetite. Furthermore, in isolated adult mice of the same weight (22±1 g), food consumption measured during 1 week did not differ between transgenic and control mice (VMAT2 sertÀcre : 3.58 ± 0.28 g; control: 3.65 ± 0.30 g; mean±SEM. n ¼ 5-6). Finally, when tested in the tail suspension test (TST), VMAT2 sertÀcre mice were more reactive than were control mice. Indeed, immobility time was reduced (Figure 6d ; À37 ± 12%; po0.01) and time spent actively struggling to escape was increased ( + 68 ± 13%, p ¼ 0.001). These observations suggested an increase in active defense behaviors of VMAT2 sertÀcre mice in the TST. sertÀcre mice (black bars). There was a highly significant decrease in 5-HT levels in all examined brain areas. ***po0.0001; Student's t-test; error bars ¼ SEM; n ¼ 5-6. (b) Tissue levels of NA in the cortex and the hippocampus and DA in the striatum. There was no change in NA in the cortex but a small reduction in the hippocampus, whereas striatal DA levels were found unchanged using the Student's t-test; n ¼ 5-6, **po0.01. (c) Levels of 5-HT in the gut and in the blood. There were no changes in the gut, whereas 5-HT was significantly decreased in the blood ***po0.0001; Student's t-test; n ¼ 5-8.
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Interestingly, VMAT2
sertÀcre mice also displayed a large increase in behavioral reactivity in response to stimulation with the innately aversive US (po0.01; Figure 7a ). In addition, VMAT2 sertÀcre mice froze less in reaction to the US than did control mice (control: 69±7% of time during the OFF periods; VMAT2 sertÀcre : 37±8%; mean±SEM.; po0.05, n ¼ 4-5, not shown).
To examine whether the change in behavioral reactivity to the US in VMAT2 sertÀcre mice was due to reduced 5-HT levels, we investigated the effects of a long-term pargyline treatment (70 mg/kg Â day, for 3 weeks). Pargyline reversed the 5-HT depletion (À94±0.01%) observed in VMAT2 sertÀcre mice, and even markedly increased 5-HT levels compared with vehicle-treated control mice (Figure 7d) . Nevertheless, after pargyline treatment, 5-HT tissue levels were still 20 ± 13% lower in VMAT2 sertÀcre mutants than in pargyline-treated control mice (Figure 7d ). Two-way ANOVA indicated a significant effect (po0.0001) of treatment F(1, 19) ¼ 574 and of genotype F(1, 19) ¼ 46, but no significant interactions (F(1, 19) ¼ 0.3). Pargyline also restored some 5-HT immunostaining in raphe neurons and axon terminals of VMAT2 sertÀcre mice (Figures 7b and  c) , although the levels were lower than those observed in controls (not shown). In response to the US, VMAT2 sertÀcre mice treated with pargyline no longer displayed their increment of flight responses compared with control mice (Figure 7a ). Two-way ANOVA indicated significant effects (p ¼ 0.01) of treatment F(1, 12) ¼ 9, genotype F(1, 12) ¼ 9, and a significant treatment Â genotype interaction F(1, 12) ¼ 10. Furthermore, there were no changes in the percentage of synaptosomes. There was less total uptake in synaptosomes from VMAT2 sertÀcre mice or from WT mice treated with the VMAT inhibitor reserpine (Vmax; VMAT2 sertÀcre ¼ 2.0±0.1 fmol/min, reserpine ¼ 2.6±0.07, mean±SEM, n ¼ 3) compared with synaptosomes from WT or SERT cre/ + mice (Vmax: control ¼ 6.8±0.5 fmol/min; SERT cre/ + ¼ 5.5±0.3, n ¼ 3). There were no significant changes (using one-way ANOVA) in the Km values between groups (WT ¼ 18.8 ± 4.5 nM; VMAT2 sertÀcre ¼ 13.5 ± 3.2 nM; SERT cre/ + ¼ 12.7 ± 3 nM; reserpine ¼ 12.25 ± 1.4 nM; means ± SEM, n ¼ 3). VMAT2 conditional deletion N Narboux-Nême et al time spent freezing in response to the US in pargylinetreated mice (control: 87 ± 6% of time during the OFF periods; VMAT2 sertÀcre : 76±24%, not shown).
DISCUSSION
Previous studies have shown that the majority of brain monoamines resides in the vesicular storage pools and that pharmacological inhibition of VMAT prevents vesicular release of 5-HT (Adell and Artigas, 1998; Bunin et al, 1998; O'Connor and Kruk, 1991) . We confirm here that VMAT2 is the only vesicular transporter implicated in this effect in the CNS, as its genetic ablation in 5-HT neurons entirely reproduced the effects on 5-HT uptake of complete VMAT inhibition with reserpine. Interestingly, however, in VMAT2 sertÀcre mice, 5-HT is probably produced at normal rates, as suggested by (1) the normal levels of TPH2 gene expression, (2) the normal amounts of 5-HIAA (the product of oxidative deamination of 5-HT), and (3) the normal increase in 5-HT levels after MAO inhibition by pargyline. Hence, all 5-HT produced or taken up by neurons, which cannot be stored into vesicles are rapidly metabolized by mitochondrial monoamine oxidases present in raphe neurons (Shih et al, 1997; Vitalis et al, 2002) . As 5-HT continues to be produced in raphe neurons at a seemingly normal rate, it can still be released. Although such release is likely to be marginal under standard conditions because of the low endogenous levels of 5-HT, it could still occur after administration of a MAOI which causes a major increase in 5-HT tissue levels. Furthermore, it cannot be excluded that pargyline could enhance some form of vesicular storage (Buu, 1989) . In both VMAT2 KO and VMAT2 sertÀcre mice, MAOIs restored some functions such as the inhibitory action of 5-HT on active defense reactions ( Figure 7b ) and normal growth Narboux-Nême et al, 2009 ). This functional restoration in vivo fits well with the potassium-and MDMA-induced releases of [ (Evans and Collard, 1988) . Although this was suggested to occur in VMAT2 KO mice (Fon et al, 1997) , we do not presently have any data in Figure 6 The VMAT2 sertÀcre mutation decreased anxiety and locomotion but increased reactivity to stress. (Njus et al, 1986) , although this passively generated gradient remains very small compared with that generated by VMAT2, it may nevertheless be a way to compensate for VMAT2 loss. (3) Finally, there is evidence for uptake of 5-HT in catecholaminergic neurons (Cases et al, 1998; Zhou et al, 2005 sertÀcre mice is likely to be different from that of WT mice. However, the relatively low calcium dependency of our release conditions in the presence of pargyline might preclude similar observation after potassium stimulation. It is also important to emphasize that in the absence of pargyline, calciumdependent vesicular release of 5-HT was not observed in VMAT2 sertÀcre mice. Reduced 5-HT levels in VMAT2 sertÀcre mice caused a sensitization of the 5-HT 1A autoreceptors coupled to Gai proteins in the dorsal raphe nucleus. In contrast, the decrease in 5-HT contents in VMAT2 sertÀcre mice caused no adaptive changes of 5-HT 1A receptors in target areas, such as the hippocampus. This is in line with the notion that raphe 5-HT 1A autoreceptors, but not hippocampal 5-HT 1A receptors, show modulation in response to changes in 5-HT levels (Fabre et al, 2000; Mannoury La Cour et al, 2006; Mongeau et al, 1997) and indicate that extracellular 5-HT level was much reduced at the level of serotonergic somas.
The VMAT2 sertÀcre mouse line offers an interesting model of hyposerotonergia, complementary to other recently described genetic mouse models (Trowbridge et al, 2010) . All recent genetic hyposerotonergic models focused on reducing 5-HT production either by targeting the central 5-HT synthesis enzyme, TPH2 (Alenina et al, 2009; Beaulieu et al, 2008; Gutknecht et al, 2008; Savelieva et al, 2008) or by invalidating the transcription factors controlling differentiation of raphe neurons such as pet1 and lmx1B (Dai et al, 2008; Hendricks et al, 2003; Kiyasova et al, 2011; Zhao et al, 2006) . The more severe 5-HT depletion observed here (À95%), compared with previous models (À70 to 90%), is likely due to the fact that increased 5-HT degradation, when VMAT2 is absent, affects all sources of 5-HT (eg, produced by TPH1/TPH2). The present observations, consistent with sertÀcre mice, and markedly increased 5-HT levels (in the hippocampus). Bonferonni's test indicated a significant decrease in 5-HT levels in VMAT2
sertÀcre mutants compared with control mice ( ### po0.001, # po0.05), and significant increases of 5-HT levels after pargyline (***po0.001) compared with control mice.
VMAT2 conditional deletion N Narboux-Nême et al Tph2 knockout mice (Alenina et al, 2009; Gutknecht et al, 2008) , showed both a normal development of the raphe neurons, and a normal density of 5-HT terminals in the hippocampus and the cerebral cortex of VMAT2 sertÀcre mice. Subtle developmental defects may nonetheless exist given the large body of evidence supporting the role of 5-HT in the maturation of neural circuits (Trowbridge et al, 2010) . Normal morphology of 5-HT neurons and brain specificity provides two major advantages of genetic models in general compared with pharmacological depletion methods such as, respectively, lesions of 5-HT neurons with 5,7-dihydroxytryptamine and depletion with p-chlorophenylalanine (PCPA). Compared with the Tph2 knockout which irreversibly inactivates 5-HT synthesis, the VMAT2 sertÀcre mutation has also the advantage of rapid reversibility through MAO inhibition as TPH2 is not targeted or downregulated. Overall, VMAT2 selective deletion should allow more direct explorations of the function of monoamine release in otherwise normally developed raphe neurons.
Behavioral characterization of VMAT2 sertÀcre mice showed that depletion of central 5-HT stores reduces anxiety. This finding is in agreement with reports in several genetic models of 5-HT-deficient mice (Dai et al, 2008; Kiyasova et al, 2011) and with numerous studies using pharmacological approaches to decrease brain 5-HT in rats (Graeff, 2004; Griebel, 1995) . Furthermore, decreased 5-HT input at several receptors (including the 5-HT 2A and 5-HT 2C subtypes) clearly reduces anxiety in mice (Heisler et al, 2007; Mongeau et al, 2010; Weisstaub et al, 2006) .
VMAT2 sertÀcre mice were first tested in the most standard model, the EPM, having a strong validity for anxiolysis mediated by the GABAergic system, but not so much, it seems from previous studies (McCreary et al, 1996) , for the serotonergic system. Indeed, the effect of altering 5-HT on behaviors observed in the EPM was argued to be the overall result of a balance between distinct 5-HT systems in different brain areas. For example, microinjection of a 5-HT 2C agonist generated opposite effects in the EPM depending on the brain areas targeted (Cornelio and Nunes-de-Souza, 2007; Nunes-de-Souza et al, 2008) . This might explain the lack of changes in VMAT2 sertÀcre mice observed here with the EPM. The observed decrease in the exploratory behavior of VMAT2 sertÀcre mice, as in other hyposerotonergic models (Dringenberg et al, 1995; Hendricks et al, 2003) , is also a confounding factor for the interpretation of EPM data. In contrast, consistent effects of 5-HT depletion have been noted in several models involving conflicts, in which reduced 5-HT tone was linked to decreased anxiety-like behaviors (Graeff, 2004) . In the NSF, which involves a conflict between the drive to feed and risk assessment behaviors triggered by the unfamiliar environment, VMAT2 sertÀcre mice showed an anxiolytic-like behavioral profile. This agrees with the anxiolytic-like effect of PCPA-induced 5-HT depletion and with observations in other 5-HT depleted mutant mice (Dai et al, 2008; Kiyasova et al, 2011) .
It is also interesting to note that VMAT2 sertÀcre mice spent more time struggling to escape than did control mice in the TST. This is coherent with observations in Tph1::Tph2 DKO mice which displayed increased struggling time in the forced swim test (FST) (Savelieva et al, 2008) . The increase of struggling or escape-like behavior of VMAT2 sertÀcre mice in the TST might be mechanistically similar to the increase in ultrasound-induced flight also observed here with these mutants. Both of these effects can potentially be accounted for by a lack of inhibitory effect of 5-HT at the midbrain level (Kiser and Lebovitz, 1975) . As far as we know, the present genetic invalidation study is the first that clearly indicates a tonic inhibitory role of endogenous 5-HT on the expression of active defense behaviors in reaction to fear stimuli. Previous pharmacological studies in rats showed that flight behaviors induced by an aversive ultrasound are decreased by the 5-HT agonist mCPP (Beckett et al, 1996) . Furthermore, treatment with the MAOI phenelzine decreased flight behavior in the mouse defense battery test, and this was mostly apparent after chronic compared to acute treatment (Griebel et al, 1998) . In our study, we have performed a long-term, rather than a short-term, MAOI treatment to optimally enhance 5-HT neurotransmission by desensitization of 5-HT 1A autoreceptors (Mongeau et al, 1997) , which were found to be hypersensitive in VMAT2 sertÀcre mice ( Figure 5 ). In relation to depression, it is generally believed that a reduced brain 5-HT tone results in depressed-like behaviors in escape-related models of depression such as the TST or the FST. However, although 5-HT is necessary for the action of antidepressant drugs in these models, 5-HT depletion with PCPA generally fails to alter baseline immobility (Cryan et al, 2005; O'Leary et al, 2007) . In contrast, depleting catecholamines in adult mice strongly increases baseline immobility in the TST (O'Leary et al, 2007) . Constitutive knockdowns of VMAT2 (VMAT2 + /À), which reduces the release of all monoamines, also results in an increased immobility in the FST and the TST (Fukui et al, 2007) . However, the present observation that selective deletion of VMAT2 in serotonergic neurons decreased, rather than increased, immobility in the TST, together with previous observation (Savelieva et al, 2008) on Tph1::Tph2 DKO mice subjected to the FST, indicate that a depletion of 5-HT is insufficient to induce depression-like behaviors in such escape-related tests.
Furthermore, the antidepressant-like effect observed in the TST in VMAT2 sertÀcre mice might not be paradoxical considering that antidepressant drugs exert their effect in the TST after acute rather than chronic treatment (Cryan et al, 2005) . It is important to emphasize here that although chronic treatments increase 5-HT neurotransmission, acute administrations do not (Mongeau et al, 1997) . The transient surges of extracellular 5-HT levels, associated with acute antidepressant drugs, trigger strong inhibition of both 5-HT neuronal firing and release through negative autoreceptors feedback (Auerbach et al, 1995; Hajos et al, 1995; Hervas and Artigas, 1998; Hjorth and Auerbach, 1994) .
Conclusion and Perspectives
Genetic invalidation of VMAT2 in 5-HT neurons provides an interesting model to test the function of endogenous 5-HT release in normally developed 5-HT raphe neurons. Using this model, we show that decrease in 5-HT results in an anxiolytic profile in a conflict test, contrasting with an increase in acute stress or innate fear stimulus-induced escape-like behaviors. Chronic treatment with a MAOI prevented the behavioral abnormality of VMAT2 sertÀcre mice in terms of defense to an innately aversive stimulus. Interestingly, flight reactions have often been used in validated models of panic disorders (Griebel et al, 1996) and chronic MAOIs are well known to be effective antipanic agents (Bakish et al, 1993) . Incidentally, these data address new questions as to whether extrasynaptic or nonvesicular 5-HT release mechanisms might be involved in the therapeutic effects of this class of antidepressant drugs.
